Katy Balls Katy Balls

Secrets of the Vaccine Taskforce’s success

issue 06 February 2021

Until a few weeks ago, the government’s track record on Covid was one of repeated failure. The death toll, the depth of the recession, the public disapproval of the government: Britain’s figures were among the worst in the world. But with vaccines, things have changed. The UK is now on track to be the first major country in the world to vaccinate its way out of lockdown.

The foreign press coverage has turned from mockery to awe, with Britain having vaccinated more people than France, Germany, Italy and Spain put together. Many of those behind this success are virtually unknown to the public. Their story matters, because the Vaccine Taskforce is already being looked to by ministers as a model for how government should work once the pandemic is over.

Its success starts with a failure: the debacle over PPE. When the virus started, Britain was supposed to unlock the reserves of plastic gloves and gowns prepared for a pandemic by Public Health England. Instead, the fiasco that followed saw the government fleeced by private consultants as countries across the world scrabbled for supply and contracts became meaningless. It was a model of what not to do.

Tensions across government ran high — with Downing Street blaming the Department of Health for the debacle. ‘It was a shitshow,’ said a No. 10 aide reflecting on that period. Sir Patrick Vallance, the chief scientific adviser, concluded that the search for a vaccine would require a new approach — picking a team of outsiders with heft and expertise.

At first, vaccines were seen as a remote possibility — officials pointed out the millions spent in vain on finding a jab for HIV. ‘It was viewed as one of several work-streams,’ says a government aide who was working in No. 10 at the time. ‘The Prime Minister’s main concern was avoiding another lockdown by whatever means available.

GIF Image

You might disagree with half of it, but you’ll enjoy reading all of it

TRY 3 MONTHS FOR $5
Our magazine articles are for subscribers only. Start your 3-month trial today for just $5 and subscribe to more than one view

Comments

Join the debate for just £1 a month

Be part of the conversation with other Spectator readers by getting your first three months for £3.

Already a subscriber? Log in